A&O advises Apax Partners and Neuraxpharm on Buccolam acquisition

Allen & Overy has advised Apax Partners and its portfolio company Neuraxpharm on the acquisition of Buccolam assets from Takeda

Apax Partners and its portfolio company Neuraxpharm Group, a leading European speciality pharmaceutical company focused on the central nervous system (CNS), have acquired the assets and rights related to prescription brand Buccolam from Takeda Pharmaceutical Company Limited, a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, in a multinational asset deal. The transaction is expected to close by the end of 2020.

Buccolam is a leading treatment for prolonged, acute, convulsive seizures (PACS) in infants, children and adolescents, with an extensive customer base across 18 countries in Europe and Israel.

Allen & Overy’s cross border experience within the healthcare and pharmaceuticals space played an important role in this transaction, which will bring a critical and highly effective treatment to new markets. The U.S. Corporate and M&A practices worked alongside colleagues in the UK, Spain and Germany to address the cross-border complexities of this transaction.

The Allen & Overy team advising Neuraxpharm Group was led by New York office M&A partner Paul Burns (pictured left), supported by teams from London, Madrid, Munich, Frankfurt and Hamburg. From the Madrid office, the support was provided by associate Marta Guardiola (pictured right).

Desire Vidal